Taylor Hoffman Wealth Management Has $3.79 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Taylor Hoffman Wealth Management boosted its position in Johnson & Johnson (NYSE:JNJ) by 0.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,974 shares of the company’s stock after buying an additional 116 shares during the period. Johnson & Johnson makes up 1.6% of Taylor Hoffman Wealth Management’s holdings, making the stock its 28th biggest holding. Taylor Hoffman Wealth Management’s holdings in Johnson & Johnson were worth $3,792,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Searle & CO. lifted its holdings in Johnson & Johnson by 1.2% in the first quarter. Searle & CO. now owns 40,962 shares of the company’s stock valued at $6,480,000 after buying an additional 500 shares during the period. Forum Financial Management LP increased its stake in Johnson & Johnson by 11.2% in the first quarter. Forum Financial Management LP now owns 23,390 shares of the company’s stock valued at $3,700,000 after purchasing an additional 2,359 shares in the last quarter. Brighton Jones LLC increased its stake in Johnson & Johnson by 3.9% in the first quarter. Brighton Jones LLC now owns 36,392 shares of the company’s stock valued at $5,757,000 after purchasing an additional 1,362 shares in the last quarter. Private Portfolio Partners LLC increased its stake in Johnson & Johnson by 1.4% in the first quarter. Private Portfolio Partners LLC now owns 10,354 shares of the company’s stock valued at $1,638,000 after purchasing an additional 146 shares in the last quarter. Finally, Wilkins Investment Counsel Inc. increased its stake in Johnson & Johnson by 47.9% in the first quarter. Wilkins Investment Counsel Inc. now owns 121,074 shares of the company’s stock valued at $19,153,000 after purchasing an additional 39,203 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on JNJ shares. Bank of America decreased their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Finally, The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Stock Down 0.5 %

JNJ opened at $154.69 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a market cap of $372.29 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 2.70 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company’s 50-day moving average price is $148.36 and its two-hundred day moving average price is $153.34.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.